基本信息
浏览量:0
职业迁徙
个人简介
Fei (Xavier) Chen, Ph.D., is a Principal Investigator of the Institute of Biomedical Sciences (IBS) and Shanghai Cancer Center at Fudan University.
Fei received his BS degree from Shandong University in 2009. After graduation, Fei joined Dr. Yanhui Xu’s laboratory at Fudan University and completed the master's training, where he focused on elucidating the structures and functions of epigenetic modifiers. In collaboration with Dr. Yujiang Shi at Harvard, he found that histone demethylase LSD2 is catalytically induced by a cofactor and demonstrated the molecular mechanisms, thus establishing a new model for the regulation of histone modifiers by cofactors (Molecular Cell, 2013; Cell Research 2013). These findings aroused his interests in chromatin biology, epigenetic modifications, and how regulatory signals are interpreted by the transcription machinery.
Therefore, Fei joined the laboratory of Dr. Ali Shilatifard, a leader in the field of epigenetics, to complete his Ph.D. thesis focusing on understanding the molecular mechanisms of transcriptional regulation. During this time, he identified transcription regulator PAF1 as a crucial player in multiple steps of transcription especially the pausing-elongation transition, a rate-limiting step for transcription activation (Cell, 2015; Genes & Development 2015). Moreover, he revealed the mechanisms underlying the roles of enhancer activation during the dynamic change of transcription, providing novel insights into the functions of cis-regulatory elements in gene expression (Science, 2017).
Aiming to apply his knowledge in transcription and epigenetics to tackle problems in human diseases such as cancer, Fei decided to extend his training by working as a postdoctoral fellow in the laboratory of Dr. Joan Massague, a pioneer in the field of cancer metastasis, at Memorial Sloan Kettering Cancer Center. During that time, he has obtained extensive knowledge and exceptional training in cancer biology with a focus on the roles of transcriptional and epigenetic dysregulation in cancer progression (Cancer Discovery, 2020).
In 2019, Fei took the faculty position at Fudan University in Shanghai and established a research laboratory aiming to elucidate the fundamental mechanisms of transcriptional and epigenetic regulation and the contribution of their dysregulation to disease, especially cancer. Since then, collaborating with Dr. Yanhui Xu, they have identified a new transcription regulator composed of Integrator and PP2A-AC (INTAC) and unraveled its function in controlling early elongation (Science, 2020). Moreover, by utilizing vigorous biochemistry and multi-omics approaches, the team has recently discovered how the axis of INTAC-P-TEFb controls the dynamic phosphorylation of SPT5, a critical regulation of transcriptional pausing and elongation, to orchestrate the progression of the transcription machinery (Molecular Cell, 2021). Together with the team, Fei aims to pursue interdisciplinary studies by using different approaches in biochemistry, bioinformatics, genetics and epigenetics, functional genomics, and cancer biology, with the ultimate goal to make impactful discoveries and benefit patients and the community.
Fei received his BS degree from Shandong University in 2009. After graduation, Fei joined Dr. Yanhui Xu’s laboratory at Fudan University and completed the master's training, where he focused on elucidating the structures and functions of epigenetic modifiers. In collaboration with Dr. Yujiang Shi at Harvard, he found that histone demethylase LSD2 is catalytically induced by a cofactor and demonstrated the molecular mechanisms, thus establishing a new model for the regulation of histone modifiers by cofactors (Molecular Cell, 2013; Cell Research 2013). These findings aroused his interests in chromatin biology, epigenetic modifications, and how regulatory signals are interpreted by the transcription machinery.
Therefore, Fei joined the laboratory of Dr. Ali Shilatifard, a leader in the field of epigenetics, to complete his Ph.D. thesis focusing on understanding the molecular mechanisms of transcriptional regulation. During this time, he identified transcription regulator PAF1 as a crucial player in multiple steps of transcription especially the pausing-elongation transition, a rate-limiting step for transcription activation (Cell, 2015; Genes & Development 2015). Moreover, he revealed the mechanisms underlying the roles of enhancer activation during the dynamic change of transcription, providing novel insights into the functions of cis-regulatory elements in gene expression (Science, 2017).
Aiming to apply his knowledge in transcription and epigenetics to tackle problems in human diseases such as cancer, Fei decided to extend his training by working as a postdoctoral fellow in the laboratory of Dr. Joan Massague, a pioneer in the field of cancer metastasis, at Memorial Sloan Kettering Cancer Center. During that time, he has obtained extensive knowledge and exceptional training in cancer biology with a focus on the roles of transcriptional and epigenetic dysregulation in cancer progression (Cancer Discovery, 2020).
In 2019, Fei took the faculty position at Fudan University in Shanghai and established a research laboratory aiming to elucidate the fundamental mechanisms of transcriptional and epigenetic regulation and the contribution of their dysregulation to disease, especially cancer. Since then, collaborating with Dr. Yanhui Xu, they have identified a new transcription regulator composed of Integrator and PP2A-AC (INTAC) and unraveled its function in controlling early elongation (Science, 2020). Moreover, by utilizing vigorous biochemistry and multi-omics approaches, the team has recently discovered how the axis of INTAC-P-TEFb controls the dynamic phosphorylation of SPT5, a critical regulation of transcriptional pausing and elongation, to orchestrate the progression of the transcription machinery (Molecular Cell, 2021). Together with the team, Fei aims to pursue interdisciplinary studies by using different approaches in biochemistry, bioinformatics, genetics and epigenetics, functional genomics, and cancer biology, with the ultimate goal to make impactful discoveries and benefit patients and the community.
研究兴趣
论文共 27 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Science Bulletin (2024)
Clinical and translational medicineno. 1 (2024): e1519-e1519
Congling Xu, Chengyu Li,Jiwei Chen,Yan Xiong,Zhibin Qiao,Pengyu Fan,Conghui Li,Shuangyu Ma, Jin Liu,Aixia Song,Bolin Tao,Tao Xu,
Cell Researchno. 5 (2023): 403-406
Cheng Zeng,Jiwei Chen, Emmalee W. Cooke, Arijita Subuddhi, Eliana T. Roodman,Fei Xavier Chen,Kaixiang Cao
Transcriptionno. 1-3 (2022): 53-69
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn